Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Phase 2 RENEW trial underway; interim data expected in H2 2026.
Already have an account? Sign in.
Phase 2 RENEW trial underway; interim data expected in H2 2026.
Rigetti stock dropped after Q3 revenue of $1.4 million missed estimates and full-year guidance of about $20 million fell short of analyst expectations.
CoreWeave shares rose after a strong Q3 beat, with revenue up more than $1B sequentially and margins hitting double digits ahead of plan.
Phase 2 FREEDOM2 results for PGN-EDODM1 deliver 46.5% mean splicing correction, functional improvements, and strong analyst support.
Be the first to know when deals break, stocks move, or biotech headlines hit.